Home

Mikael Dolsten

CIK 1437590 · President R&D · last filed 2026-09-09

Mikael Dolsten is a President R&D who has filed 123 SEC Form 4 insider transactions across 7 companies since 2008. The most recent filing shows the insider sold $96.0K of A on Sep 9, 2026. Across all open-market trades the lifetime net is −$31.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $9.9M across reported positions. 63 SEC filings were submitted jointly with PFIZER INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$9.92M

Companies

7

Total Filings

123

Lifetime Open-Market Net

-$31.80M

Filer Profile

Reported Address
C/O AGILENT TECHNOLOGIES, INC.
5301 STEVENS CREEK BLVD.
SANTA CLARA, CA 95051
Related Filers
PFIZER INC — 63 joint filings, latest 2025-05-23
AGILENT TECHNOLOGIES INC — 12 joint filings, latest 2026-09-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
A Director 4,923 $146.93 $723.4K -$702.2K 9 2026-09-09
RCKT Director 67,082 $3.35 $224.7K $0 1 2026-07-06
Apellis Pharmaceuticals, Inc. (APLS) Delisted Director 0 $41.03 $0 $0 2 2026-05-14
RCKTW Director 44,220 $0.00 $88 $0 3 2025-07-18
PFE President R&D 323,710 $27.72 $8.97M -$31.09M 93 2024-09-16
KPTI Director — $1.61 — $0 8 2021-05-21
WYETH (WYE) Delisted Sr. VP & Pres., Wyeth Research — — — $0 1 2008-06-18

Recent Filings

123 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-09 A Sell (S) −634 -$96.0K EDGAR
2026-09-04 A Notice (144) −634 -$96.0K EDGAR
2026-07-06 RCKT Grant (A) +22,862 $0 EDGAR
2026-06-02 A Sell (S) −1,600 -$216.7K EDGAR
2026-05-29 A Notice (144) −1,600 -$216.7K EDGAR
2026-05-14 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed −28,624 $0 EDGAR
2026-03-23 A Grant (A) +2,158 $241.2K EDGAR
2026-03-03 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +14,312 $0 EDGAR
2025-12-03 A Sell (S) −2,600 -$389.5K EDGAR
2025-12-01 A Notice (144) −2,600 -$389.5K EDGAR
Showing 1–10 of 123
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.